Delaware | 001-34962 | 20-5300780 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
5858 Horton Street, #455, Emeryville, CA | 94608 | |
(Address of Principal Executive Offices) | (Zip Code) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit No. | Description | |
99.1 | Press Release, dated March 10, 2016 |
ZOGENIX, INC. | ||||||
Date: March 10, 2016 | By: | /s/ Ann D. Rhoads | ||||
Name: | Ann D. Rhoads | |||||
Title: | Executive Vice President, Chief Financial Officer, Treasurer and Secretary |
Exhibit No. | Description | |
99.1 | Press Release, dated March 10, 2016 |
• | Investigational New Drug (IND) Application for the Phase 3 program for ZX008 for the treatment of Dravet syndrome, a rare and debilitating form of epilepsy that begins in infancy, accepted by the U.S. Food and Drug Administration (FDA). |
• | Initiated the first Phase 3 clinical trial of ZX008 in the U.S. |
• | Recently received first national approvals towards commencing the second Phase 3 clinical trial for ZX008 in Europe. |
• | Received Fast Track designation from the FDA for ZX008 in Dravet syndrome. |
• | Announced new data demonstrating sustained effectiveness and cardiovascular-related safety in a new cohort of 7 Dravet syndrome patients who began add-on treatment with ZX008 at various starting points between 2010 and 2014. |
• | Completed the year ended December 31, 2015, with $155.3 million in cash and cash equivalents. Zogenix’s expected cash runway extends through 2017. |
• | Total revenue for the fourth quarter of 2015 was $6.1 million, and reflected $5.3 million of contract manufacturing revenue and $0.8 million of service and other product revenue. This compared with total revenue of $9.9 million in the same quarter last year, which included $8.9 million of contract manufacturing revenue and $1.0 million of service and other product revenue. The decrease in contract manufacturing revenue in the fourth quarter of 2015 was due to the timing of shipments of Sumavel® DosePro® to Endo International Plc under the supply agreement between the two companies. |
• | Fourth quarter 2015 research and development expenses totaled $8.6 million, up from $3.3 million in the fourth quarter a year ago, as the Company continued preparations for its two Phase 3 studies for ZX008. |
• | Fourth quarter 2015 selling, general and administrative expenses totaled $6.8 million, compared with $5.8 million in the fourth quarter a year ago. |
• | Net loss from continuing operations for the fourth quarter of 2015 was $11.9 million, compared with $9.6 million in the same quarter a year ago. |
• | Net income from discontinued operations was $3.0 million for the fourth quarter of 2015, compared with a net loss of $10.9 million in the fourth quarter a year ago, and reflects revenues recorded from Zohydro prescriptions and final allocation of income taxes between continuing and discontinued operations. |
• | Total net loss for the fourth quarter of 2015 was $8.8 million, or $0.36 per share, compared with a net loss of $20.5 million, or $1.09 per share, for the fourth quarter a year ago. |
• | Total revenue for the year ended December 31, 2015 was $27.2 million, and reflected $24.4 million of contract manufacturing revenue and $2.8 million of service and other product revenue. This compared with total revenue of $28.9 million in the same period last year, which included $15.4 million of contract manufacturing revenue and $13.6 million of net product and service revenue. The increase in contract manufacturing revenue and decrease in net product revenue in the year ended December 31, 2015 was due to the sale of Sumavel DosePro to Endo International Plc in May 2014 and subsequent performance under the supply agreement between the two companies. |
• | Research and development expenses for the year ended December 31, 2015 totaled $27.9 million, up from $11.9 million in the year ago period, as the Company continued preparations for its two Phase 3 studies for ZX008 and the multi-dose clinical study for ReldayTM. |
• | Selling, general and administrative expenses for the year ended December 31, 2015 totaled $26.3 million, compared with $34.6 million in the year ago period. The Company incurred selling expenses for Sumavel DosePro prior to its sale in May 2014. |
• | Net loss from continuing operations for the year ended December 31, 2015 was $41.7 million, compared with net income from continuing operations of $61.5 million in the same period a year ago, which includes the pre-tax gain on the sale of Sumavel DosePro. |
• | Net income from discontinued operations for the year ended December 31, 2015 was $67.8 million, compared to a net loss of $52.9 million in the year ago period. Income from discontinued operations in 2015 includes a gain on the sale of the Zohydro business of $75.4 million, net of applicable tax expense. |
• | Total net income for the year ended December 31, 2015 was $26.1 million, or $1.22 per share, compared with net income of $8.6 million, or $0.48 per share, for the year ended December 31, 2014. |
• | Cash and cash equivalents at December 31, 2015 totaled $155.3 million. |
• | Research and development expenses are expected to be $54-59 million, reflecting initiation and ramp-up of ZX008 clinical studies; |
• | Selling, general and administrative expenses are expected to be $25-27 million; and |
• | Contract manufacturing revenue from the supply of Sumavel DosePro to Endo is expected at a low single-digit markup over cost of contract manufacturing. |
Three Months Ended | Twelve Months Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||
Revenues: | |||||||||||||||
Contract manufacturing revenue | $ | 5,325 | $ | 8,929 | $ | 24,369 | $ | 15,392 | |||||||
Net product revenue | — | — | — | 9,840 | |||||||||||
Service and other product revenue | 756 | 1,009 | 2,813 | 3,715 | |||||||||||
Total revenue | 6,081 | 9,938 | 27,182 | 28,947 | |||||||||||
Operating (income) expense: | |||||||||||||||
Cost of contract manufacturing | 4,850 | 8,423 | 22,356 | 14,342 | |||||||||||
Cost of goods sold | — | — | — | 5,263 | |||||||||||
Royalty expense | 96 | 80 | 345 | 591 | |||||||||||
Research and development | 8,550 | 3,278 | 27,860 | 11,893 | |||||||||||
Selling, general & administrative | 6,801 | 5,836 | 26,347 | 34,639 | |||||||||||
Change in fair value of contingent consideration | (100 | ) | — | (2,000 | ) | — | |||||||||
Impairment of long-lived assets | — | — | — | 838 | |||||||||||
Net gain on sale of business | — | — | — | (79,980 | ) | ||||||||||
Total operating (income) expense | 20,197 | 17,617 | 74,908 | (12,414 | ) | ||||||||||
Income (loss) from operations | (14,116 | ) | (7,679 | ) | (47,726 | ) | 41,361 | ||||||||
Other income (expense): | |||||||||||||||
Interest expense, net | (700 | ) | (89 | ) | (2,959 | ) | (3,070 | ) | |||||||
Loss on early extinguishment of debt | — | — | — | (1,254 | ) | ||||||||||
Change in fair value of warrant liabilities | (242 | ) | (1,086 | ) | (1,103 | ) | 25,332 | ||||||||
Change in fair value of embedded derivatives | — | — | — | (14 | ) | ||||||||||
Investment loss | (261 | ) | — | (5,746 | ) | — | |||||||||
Other income (expense) | (15 | ) | (743 | ) | (71 | ) | (784 | ) | |||||||
Total other income (expense) | (1,218 | ) | (1,918 | ) | (9,879 | ) | 20,210 | ||||||||
Net income (loss) from continuing operations before income taxes | (15,334 | ) | (9,597 | ) | (57,605 | ) | 61,571 | ||||||||
Benefit for income taxes | 3,472 | (39 | ) | 15,901 | (84 | ) | |||||||||
Net income (loss) from continuing operations | (11,862 | ) | (9,636 | ) | (41,704 | ) | 61,487 | ||||||||
Income (loss) from discontinued operations, net of applicable tax | 3,019 | (10,884 | ) | 67,848 | (52,900 | ) | |||||||||
Net income | $ | (8,843 | ) | $ | (20,520 | ) | $ | 26,144 | $ | 8,587 | |||||
Net income per share, basic | $ | (0.36 | ) | $ | (1.09 | ) | $ | 1.22 | $ | 0.48 | |||||
Net income per share, diluted | $ | (0.36 | ) | $ | (1.09 | ) | $ | 1.22 | $ | 0.48 | |||||
Weighted average shares outstanding, basic | 24,764 | 18,752 | 21,449 | 17,825 | |||||||||||
Weighted average shares outstanding, diluted | 24,764 | 18,752 | 21,449 | 17,855 |
December 31, | December 31, | ||||||
2015 | 2014 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 155,349 | $ | 42,205 | |||
Restricted cash | 10,002 | 8,500 | |||||
Trade accounts receivable, net | 1,396 | 6,078 | |||||
Inventory | 12,030 | 11,444 | |||||
Prepaid expenses and other current assets | 5,611 | 2,555 | |||||
Current assets of discontinued operations | 208 | 7,196 | |||||
Total current assets | 184,596 | 77,978 | |||||
Property and equipment, net | 9,254 | 10,618 | |||||
Intangible assets | 102,500 | 102,500 | |||||
Goodwill | 6,234 | 6,234 | |||||
Other assets | 3,403 | 2,832 | |||||
Noncurrent assets of discontinued operations | 0 | 2,673 | |||||
Total assets | $ | 305,987 | $ | 202,835 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 5,290 | $ | 4,742 | |||
Accrued expenses | 8,328 | 9,173 | |||||
Common stock warrant liabilities | 6,196 | 5,093 | |||||
Revolving credit facility | — | 1,450 | |||||
Long-term debt, current portion | 6,414 | — | |||||
Deferred revenue | 945 | 1,472 | |||||
Current liabilities of discontinued operations | 2,906 | 22,307 | |||||
Total current liabilities | 30,079 | 44,237 | |||||
Long-term debt, less current portion | 15,971 | 21,703 | |||||
Deferred revenue, less current portion | 6,139 | 7,063 | |||||
Contingent purchase consideration | 51,000 | 53,000 | |||||
Deferred income taxes | 18,450 | 20,500 | |||||
Other long-term liabilities | 1,588 | 1,053 | |||||
Stockholders’ equity | 182,760 | 55,279 | |||||
Total liabilities and stockholders’ equity | $ | 305,987 | $ | 202,835 |